Palmitic acid-modified poly-L-lysine for non-viral delivery of plasmid DNA to skin fibroblasts

被引:31
作者
Abbasi, Meysam
Uludag, Hasan [1 ]
Incani, Vanessa
Olson, Cori
Lin, Xiaoyue
Clements, Basak Acan
Rutkowski, Dorothy
Ghahary, Aziz
Weinfeld, Michael
机构
[1] Univ Alberta, Dept Biomed Engn, Edmonton, AB T6G 2M7, Canada
[2] Univ Alberta, Fac Med & Dent, Edmonton, AB T6G 2M7, Canada
[3] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2M7, Canada
[4] Univ Alberta, Fac Engn, Edmonton, AB T6G 2M7, Canada
[5] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2M7, Canada
[6] Univ Alberta, Fac Med & Dent, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2M7, Canada
[7] Univ British Columbia, Dept Surg, Vancouver, BC V5Z 1M9, Canada
[8] Cross Canc Inst, Edmonton, AB, Canada
关键词
D O I
10.1021/bm060940x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Palmitic acid conjugates of poly-L-lysine (PLL-PA) were prepared, and their ability to deliver plasmid DNA into human skin fibroblasts was evaluated in vitro. The conjugates were capable of condensing a 4.7 kb plasmid DNA into 50-200 nm particles (mean +/- SD = 112 +/- 34 nm), which were slightly smaller than the particles formed by PLL (mean +/- SD = 126 +/- 51 nm). Both PLL and PLL-PA were readily taken up by the cells, but PLL-PA delivered the plasmid DNA into a higher proportion of cells. DNA delivery was found to be reduced by endocytosis inhibitor Brefeldin A, suggesting an active mechanism of particle uptake. Using enhanced green fluorescent protein (EGFP) as a reporter gene, PLL-PA was found to give the highest number of EGFP-positive cells among several carriers tested, including polyethyleneimine, Lipofectamine-2000, and an adenovirus. Although some carriers gave a higher percentage of EGFP-positive cells than PLL-PA, they were also associated with higher toxicities. We conclude that PLL-PA is a promising gene carrier for non-viral modification of human fibroblasts.
引用
收藏
页码:1059 / 1063
页数:5
相关论文
共 30 条
[1]  
ACANCLEMENS B, 2006, BIOMACROMOLECULES, V7, P1481
[2]   HUMAN GENE-THERAPY [J].
ANDERSON, WF .
SCIENCE, 1992, 256 (5058) :808-813
[3]   Immune responses to gene therapy vectors: influence on vector function and effector mechanisms [J].
Bessis, N ;
GarciaCozar, FJ ;
Boissier, MC .
GENE THERAPY, 2004, 11 (Suppl 1) :S10-S17
[4]   Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins [J].
Brill-Almon, E ;
Stern, B ;
Afik, D ;
Kaye, J ;
Langer, N ;
Bellomo, S ;
Shavit, M ;
Pearlman, A ;
Lippin, Y ;
Panet, A ;
Shani, N .
MOLECULAR THERAPY, 2005, 12 (02) :274-282
[5]   Supramolecular structure and nuclear targeting efficiency determine the enhancement of transfection by modified polylysines [J].
Chan, CK ;
Senden, T ;
Jans, DA .
GENE THERAPY, 2000, 7 (19) :1690-1697
[6]   Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio [J].
Chen, Y ;
Miller, WM ;
Aiyar, A .
BIOTECHNOLOGY PROGRESS, 2005, 21 (01) :274-282
[7]   Lipid-modified proteins as biomarkers for cardiovascular disease: a review [J].
Ferri, N ;
Paoletti, R ;
Corsini, A .
BIOMARKERS, 2005, 10 (04) :219-237
[8]   A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides [J].
Fischer, R ;
Köhler, K ;
Fotin-Mleczek, M ;
Brock, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) :12625-12635
[9]   Modified linear polyethylenimine-cholesterol conjugates for DNA complexation [J].
Furgeson, DY ;
Chan, WS ;
Yockman, JW ;
Kim, SW .
BIOCONJUGATE CHEMISTRY, 2003, 14 (04) :840-847
[10]   Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa [J].
Gache, Y ;
Baldeschi, C ;
Del Rio, M ;
Gagnoux-Palacios, L ;
Larcher, F ;
Lacour, JP ;
Meneguzzi, G .
HUMAN GENE THERAPY, 2004, 15 (10) :921-933